To investigate the efficacy of tamsulosin, a selective alpha-1 blocker, in lower urinary tract symptoms (LUTS) patients with metabolic syndrome (MS).
This prospective, multi-center, clinical trial included men and women (20-75 years old) with LUTS, with or without MS.
Patients were categorized as MS+ or MS-, respectively, and all of them were administered tamsulosin 0. 2 mg per oral (P. O. ) once daily for 24 weeks. Patients were assessed based on the International Prostate Symptom Score (IPSS), King's Health Questionnaire (KHQ), Overactive Bladder Questionnaire (OAB-Q), uroflowmetry with post-void residuals, and MS factors (blood pressure, waist-hip ratio, and serum levels of fasting blood glucose [FBG], triglyceride [TG], and high-density lipoprotein cholesterol) at baseline and 4, 12, and 24 weeks of treatment.
Ninety-two patients were enrolled in this study (53/92 were MS- [57. 6 %]; 39/92 were MS+ [42. 4%]). After 24 weeks of tamsulosin treatment, FBG (p = 0. 02) and TG (p < 0. 001) levels of changes were significantly greater in the MS+ group than MS- group. Total IPSS, total OAB-Q score, and the scores of each question on the KHQ showed significant improvement after treatment without intergroup differences. In KHQ, although improvements in emotional status, sleep quality, fatigue, and personal distress were greater in the MS+ group (p = 0. 05), the difference between the groups did not reach statistical significance.
Tamsulosin was effective in both LUTS patients with and without MS. Furthermore, tamsulosin had beneficial effects on some of the factors associated with MS.
Urology. 2015 Nov 04 [Epub ahead of print]
Hana Yoon, Hyun Suk Yoon, Yong Seong Lee, Sung Tae Cho, Deok Hyun Han
Department of Urology, Ewha Womans University School of Medicine. Department of Urology, Ewha Womans University School of Medicine. , Hallym University College of Medicine. , Hallym University College of Medicine. , Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.